Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to $396.1 million.

  • Ironwood Pharmaceuticals' Liabilities and Shareholders Equity rose 167.98% to $396.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1639.51%. This contributed to the annual value of $350.9 million for FY2024, which is 2550.88% down from last year.
  • Ironwood Pharmaceuticals' Liabilities and Shareholders Equity amounted to $396.1 million in Q3 2025, which was up 167.98% from $342.9 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity registered a high of $1.2 billion during Q1 2023, and its lowest value of $327.2 million during Q1 2025.
  • In the last 5 years, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity had a median value of $599.3 million in 2021 and averaged $705.7 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 12708.72% in 2021, then tumbled by 6201.61% in 2024.
  • Over the past 5 years, Ironwood Pharmaceuticals' Liabilities and Shareholders Equity (Quarter) stood at $1.1 billion in 2021, then decreased by 2.34% to $1.1 billion in 2022, then tumbled by 57.2% to $471.1 million in 2023, then fell by 25.51% to $350.9 million in 2024, then grew by 12.87% to $396.1 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $396.1 million for Q3 2025, versus $342.9 million for Q2 2025 and $327.2 million for Q1 2025.